Skip to content

Study · Non-randomized trial · 1997

4 results

Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.

Holloway L, Kohlmeier L, Kent K, Marcus R

The Journal of clinical endocrinology and metabolism1 Apr 1997Cited by 35 (Europe PMC)

PMID9100582 (opens in a new tab)DOI10.1210/jcem.82.4.3901 (opens in a new tab)PepBankPUB-09100582
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In osteopenic postmenopausal women, lumbar spine BMD did not significantly change with placebo followed by salmon calcitonin.

    In plain wordsIn postmenopausal women, spine bone density did not significantly change with placebo followed by calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeLumbar spine BMD
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 U/day for 5 days per cycle · injection · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    No significant change occurred in women receiving placebo plus CT or combined placebo.
    3 context sentences
    Summary · context
    Groups receiving GH plus CT or GH plus placebo increased lumbar spine BMD at 2 yr by 2.70 +/- 0.81% (P < 0.01) and 1.72 +/- 0.74% (P < 0.05; intention to treat analysis).
    Summary · context
    The design of the study was a randomized clinical trial consisting of 12 56-day treatment cycles.
    Summary · context
    Cycles of hormone administration consisted of 7 daily injections of recombinant GH (20 micrograms/kg.day) or its placebo, followed by 5 daily injections of salmon CT (100 U/day) or its placebo.
  2. 02HumanNon-randomized trialEfficacy outcome

    In osteopenic postmenopausal women, total hip BMD increased significantly in groups given placebo plus salmon calcitonin or GH plus placebo, with increases of 1-2% reported for the two groups together.

    In plain wordsIn postmenopausal women, hip bone density rose by 1-2% in groups given placebo then calcitonin or growth hormone plus placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseTotal hip BMD
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 U/day for 5 days per cycle · injection · 2 yearsAs given in this study (human).

    Measurements

    Total hip BMD increase
    1 to 2%
    GH plus placebo and placebo plus CT groups, reported together

    Source sentences

    Summary
    Significant increases in total hip BMD of 1-2% were observed for the GH plus placebo and placebo plus CT groups, with a nonsignificant trend in the GH plus CT group.
    2 context sentences
    Summary · context
    The design of the study was a randomized clinical trial consisting of 12 56-day treatment cycles.
    Summary · context
    Cycles of hormone administration consisted of 7 daily injections of recombinant GH (20 micrograms/kg.day) or its placebo, followed by 5 daily injections of salmon CT (100 U/day) or its placebo.
  3. 03HumanNon-randomized trialEfficacy outcome

    In osteopenic postmenopausal women, femoral trochanter BMD significantly increased with placebo followed by calcitonin.

    In plain wordsIn postmenopausal women, bone density at the femoral trochanter increased with placebo followed by calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseFemoral trochanter BMD
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 U/day for 5 days per cycle · injection · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    For the femoral trochanter, significant increases were observed in the GH plus CT and placebo plus CT groups only.
    2 context sentences
    Summary · context
    The design of the study was a randomized clinical trial consisting of 12 56-day treatment cycles.
    Summary · context
    Cycles of hormone administration consisted of 7 daily injections of recombinant GH (20 micrograms/kg.day) or its placebo, followed by 5 daily injections of salmon CT (100 U/day) or its placebo.
  4. 04HumanNon-randomized trialEfficacy outcome

    In osteopenic postmenopausal women, femoral neck BMD did not significantly change with placebo followed by calcitonin.

    In plain wordsIn postmenopausal women, femoral neck bone density did not significantly change with placebo followed by calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeFemoral neck BMD
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 U/day for 5 days per cycle · injection · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    No significant change in femoral neck BMD was observed in any group.
    2 context sentences
    Summary · context
    The design of the study was a randomized clinical trial consisting of 12 56-day treatment cycles.
    Summary · context
    Cycles of hormone administration consisted of 7 daily injections of recombinant GH (20 micrograms/kg.day) or its placebo, followed by 5 daily injections of salmon CT (100 U/day) or its placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.